Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
FibroGen (FGEN)
NASDAQ:FGEN
FGEN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.18 - $2.80
Previous CloseN/A
Volume937.77K
Average Volume (3M)1.03M
Market Cap
$58.95M
Enterprise Value$44.09M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.03
Next Earnings
Mar 03, 2025EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.23
Shares Outstanding100,770,150
10 Day Avg. Volume724,155
30 Day Avg. Volume1,027,174
Standard Deviation0.30
R-Squared0.02
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.33
Price to Cash Flow (P/CF)-1.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.34
Enterprise Value/Ebitda-0.42
Forecast
1Y Price Target
$10.00Price Target Upside1198.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
FibroGen News
PremiumCompany Announcements
FibroGen Sells Subsidiary to AstraZeneca for $160M
---
Bulls Say, Bears Say
Bulls Say
Financial HealthFibroGen's sale of its China operations to AstraZeneca is expected to bring in approximately $160 million, strengthening the company's cash position.
Revenue And Market OpportunitiesRoxadustat's approval in 45 countries for treating anemia provides a stable revenue stream and reduces the need for dilutive capital raises.
Bears Say
Investor SentimentA combination of the majority of revenue being generated in ex.-U.S. markets, and the asset's previous failure in CKD-anemia in the U.S., is preventing traction with the investors.
---
Ownership Overview
2.96% Insiders
12.38% Mutual Funds
14.52% Other Institutional Investors
64.98% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
FGEN FAQ
What was FibroGen’s price range in the past 12 months?
FibroGen lowest stock price was $0.18 and its highest was $2.80 in the past 12 months.
What is FibroGen’s market cap?
FibroGen’s market cap is $58.95M.
When is FibroGen’s upcoming earnings report date?
FibroGen’s upcoming earnings report date is Mar 03, 2025 which is in 10 days.
How were FibroGen’s earnings last quarter?
FibroGen released its earnings results on Nov 12, 2024. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.306 by $0.136.
Is FibroGen overvalued?
According to Wall Street analysts FibroGen’s price is currently Undervalued.
Does FibroGen pay dividends?
FibroGen does not currently pay dividends.
What is FibroGen’s EPS estimate?
FibroGen’s EPS estimate is -0.14.
How many shares outstanding does FibroGen have?
FibroGen has 100,770,150 shares outstanding.
What happened to FibroGen’s price movement after its last earnings report?
FibroGen reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.306. Following the earnings report the stock price went down -15.385%.
Which hedge fund is a major shareholder of FibroGen?
Currently, no hedge funds are holding shares in FGEN
---
FibroGen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (1198.70% Upside)
$10.00 (1198.70% Upside)
Blogger Sentiment
Bearish
FGEN Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Neutral
Last 7 Days >0.1%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-74.33%
12-Months-Change
Fundamentals
Return on Equity
60.38%
Trailing 12-Months
Asset Growth
-42.57%
Trailing 12-Months
Company Description
FibroGen
FibroGen, Inc. engages in the discovery, development, and commercialization of therapeutics. It focuses on hypoxia-inducible factor and connective tissue growth factor biology to develop innovative medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.
---
FGEN Company Deck
---
FGEN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook primarily driven by the robust performance of Roxadustat in China and effective cost management. However, there are challenges with decreased development revenue and uncertainties in expanding Roxadustat in new markets.Read More>---
FGEN Stock 12 Month Forecast
Average Price Target
$10.00
▲(1198.70% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Exelixis
―
Gilead Sciences
―
Regeneron
―
Vertex Pharmaceuticals
―
Best Analysts Covering FGEN
1 Year
1 Year Success Rate
1/1 ratings generated profit
1 Year Average Return
+47.00%
reiterated a buy rating 3 days ago
Copying Matthew Keller's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +47.00% per trade.
---